Melanotan II

Melanotan II was developed at the University of Arizona in the early 1990s as part of a research program seeking a safer tanning agent to reduce UV exposure and skin cancer risk. The rationale was straightforward: if people could tan without UV radiation, they would have less reason to sun-expose. The compound proved potent — producing dramatic tanning, but also highly active sexual arousal effects that became defining features of its profile. The sexual arousal side effect from Melanotan II led to the development of PT-141 (Bremelanotide) — a modified analog that retained the sexual arousal mechanism while minimizing the tanning and other effects. PT-141 subsequently achieved FDA approval for HSDD, while Melanotan II itself was never brought to market. Melanotan II activates multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R) non-selectively. MC1R activation produces melanin synthesis (tanning); MC4R activation produces sexual arousal and appetite suppression; MC3R activation has metabolic effects. This lack of selectivity drives both the range of effects and the side effect burden.

Tanning induction — rapid, UV-independent melanin production — is the compound's most distinctive effect. Users report significant darkening of skin tone within 1–2 weeks of regular dosing, which is maintained with periodic maintenance dosing and does not require sun exposure, though UV exposure during an active Melanotan II protocol amplifies and accelerates the tanning response. Libido enhancement via MC4R activation is potent and rapid. Sexual desire and erectile response are reliably enhanced — often to a degree that users describe as significantly more powerful than their baseline, which creates both the appeal and the management challenges (spontaneous erections in men). Appetite suppression from MC4R and MC3R activation is meaningful. Some users exploit this for fat loss, finding Melanotan II reduces hunger significantly enough to make caloric restriction easier. This effect is dose-dependent.

Nausea is the most common and immediate adverse effect, typically appearing 20–60 minutes after injection and lasting 1–2 hours. Severity is dose-dependent and often improves with repeated exposure as tolerance to this specific effect develops. First doses should always be very low (0.1–0.25 mg) to calibrate sensitivity. Facial flushing — warmth and redness — accompanies most injections and is generally brief. Spontaneous and prolonged erections in men are a genuine management challenge at higher doses. This can be embarrassing and occasionally uncomfortable. Dose reduction is the primary management strategy. Mole and nevi changes are the most medically significant concern. Melanotan II reliably darkens all melanocytic tissue — including existing moles, which can visually mimic changes associated with malignant melanoma. Mole darkening itself does not indicate cancer, but it complicates dermatological monitoring and theoretically could stimulate growth of pre-existing atypical cells. Regular dermatological evaluation is strongly recommended for any Melanotan II user. Hypertension (blood pressure elevation) occurs acutely post-injection.

Starting dose: 0.1–0.25 mg. This is critical — Melanotan II's dose sensitivity means beginning at even 0.5 mg causes severe nausea in many users. The compound requires careful titration. Titration: Increase by 0.1–0.25 mg per injection every 2–4 days as tolerance to nausea develops. Most users find their optimal dose between 0.5–1 mg per injection. Loading phase: Daily injections until desired pigmentation is achieved (typically 2–4 weeks at effective dose). Maintenance: Once desired pigmentation is achieved, weekly or bi-weekly injections maintain color. Melanotan II's effects are semi-permanent — pigmentation fades over weeks to months after stopping. Timing: Evening injection is recommended to minimize the impact of nausea and erection side effects on daily activity.

United States: Research chemical — not FDA approved, not a controlled substance, legally purchasable. FDA has issued warnings against Melanotan II due to safety concerns about the unregulated market. United Kingdom and Australia: Melanotan II is more explicitly regulated. The UK MHRA has issued strong warnings; Australia's TGA classifies it as prohibited. Importation is illegal in these jurisdictions. WADA: Not on the WADA prohibited list, though the mole-monitoring concern remains regardless of competitive status.

Melanotan II is typically used standalone given its potent, multifaceted effect profile. Combining it with other compounds increases side effect management complexity. Melanotan II + antiemetic: Many users pre-dose with an OTC antiemetic (dimenhydrinate, meclizine) to manage nausea during the loading phase. This is management rather than stacking, but is considered standard practice.

Melanotan II — Common Questions